21st Jul 2016 11:19
LONDON (Alliance News) - Shire PLC said Thursday that it is launching a paediatric indication for immunodeficiency treatment HyQvia across Europe.
This follows marketing authorisation which was granted by the European Commission to Baxalta, which Shire recently completed the acquisition of, last month.
Shire is introducing the new indication across member states in Europe, starting this month with Germany, The Netherlands, Ireland, Greece, Slovakia, Denmark, Sweden and Norway.
"We are pleased to bring paediatric patients a new therapeutic option as we build on our broad immunoglobulin portfolio for patients with immune deficiencies," said Shire Head of Global Product Strategy Ueli Fankhauser.
"We intend to expand the availability of HyQvia to more patients in additional geographies, with the goal of reducing the treatment burden for patients worldwide," Fankhauser in a statement.
Shares in Shire were down 0.1% at 4,932.00 pence Thursday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire